すべての画像(2)
About This Item
実験式（ヒル表記法）:
Ru
CAS番号:
分子量:
101.07
MDL番号:
UNSPSCコード:
12141739
PubChem Substance ID:
NACRES:
NA.23
おすすめの製品
アッセイ
99.9%
形状
foil
メーカー／製品名
Goodfellow 078-442-49
抵抗性
7.1 μΩ-cm, 0°C
L × W ×厚み
10 mm × 10 mm × 1.0 mm
bp
3900 °C (lit.)
mp
2310 °C (lit.)
密度
12.45 g/cm3 (lit.)
SMILES記法
[Ru]
InChI
1S/Ru
InChI Key
KJTLSVCANCCWHF-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
For updated SDS information please visit www.goodfellow.com.
法的情報
Goodfellow製品
保管分類コード
13 - Non Combustible Solids
WGK
nwg
引火点(°F)
Not applicable
引火点(℃)
Not applicable
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Nicole L Fry et al.
Accounts of chemical research, 44(4), 289-298 (2011-03-03)
Nitric oxide (NO) can induce apoptosis (programmed cell death) at micromolar or higher doses. Although cell death via NO-induced apoptosis has been studied quite extensively, the targeted delivery of such doses of NO to infected or malignant tissues has not
Lutz Ackermann et al.
Topics in current chemistry, 292, 211-229 (2010-01-01)
Stoichiometric cycloruthenation reactions of substrates containing Lewis-basic functionalities set the stage for efficient ruthenium-catalyzed C-H bond functionalization reactions. Thereby, selective addition reactions of C-H bonds across alkenes or alkynes enabled atom-economical synthesis of substituted arenes. More recently, ruthenium-catalyzed direct arylation
Martin R Gill et al.
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
A Bergamo et al.
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
Aviva Levina et al.
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）